Led by $200m venture financing of Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings and T Rowe Price Associates, total medical devices industry cross border venture financing deals worth $823.59m were announced in North America in Q4 2020, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 31.2% over the previous quarter and a rise of 16.9% when compared with the last four-quarter average of $704.66m.
North America held a 65.89% share of the global medical devices industry cross border venture financing deal value that totalled $1.25bn in Q4 2020. With a 64.90% share and deals worth $811.3m, the US was the top country in North America’s cross border venture financing deal value across medical devices industry.
In terms of deal activity, North America recorded 26 cross border deals during Q4 2020, marking an increase of 8.33% over the previous quarter and a rise of 13.04% over the last four-quarter average. The US recorded 24 deals during the month.
North America medical devices industry cross border venture financing deals in Q4 2020: Top deals
The top five cross border venture financing deals accounted for 66.8% of the overall value during Q4 2020.
The combined value of the top five medical devices cross border venture financing deals stood at $550m, against the overall value of $823.59m recorded for the quarter.
The top five medical devices cross border deals of Q4 2020 tracked by GlobalData were:
1) Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings and T Rowe Price Associates’ $200m venture financing of Tempus Labs
2) The $150m venture financing of Singlera Genomics by CICC Kai Tak Fund, DETONG Capital Partners, FutureX Skyline Capital, Huamei International, Linden Asset Management, Prosperico Ventures, Proxima Ventures, Shanghai Free Trade Zone Fund Tao Capital, Shanghai Furong Investment, Shenzhen Green Pine Capital Partners and Wuxi Financial Investment
3) 5AM Venture Management, Arboretum Ventures, CrimsoNox Capital, EDBI, Forth Management, Jazz Venture Partners, Novartis, Pilot House Ventures Group, Quad Investment Management, Sarissa Capital Management, Shanda Group, SoftBank Vision Fund II and Temasek Holdings (Private)’s $80m venture financing of Pear Therapeutics
4) The $65m venture financing of AliveCor by Bold Capital Partners, Khosla Ventures, Omron Healthcare, Qualcomm Ventures and WP Global Partner
5) Asset Management Ventures, Franklin Templeton Investments, Jonathan Fielding, King River Capital, Lightspeed Ventures, Ltd., Olive Tree Capital, SteelSky Ventures and Weili Dai’s venture financing of LARK HEALTH for $55m.
Verdict deals analysis methodology
This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.